| Schedule of worldwide net revenues |
The following table details AbbVie’s worldwide net revenues: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended September 30, | | Nine months ended September 30, | | | | (in millions) | | 2023 | | 2022 | | 2023 | | 2022 | | Immunology | | | | | | | | | Humira | United States | $ | 3,020 | | | $ | 4,956 | | | $ | 9,420 | | | $ | 13,613 | | | International | 527 | | | 603 | | | 1,680 | | | 2,045 | | | Total | $ | 3,547 | | | $ | 5,559 | | | $ | 11,100 | | | $ | 15,658 | | | Skyrizi | United States | $ | 1,875 | | | $ | 1,221 | | | $ | 4,648 | | | $ | 3,081 | | | International | 251 | | | 176 | | | 721 | | | 508 | | | Total | $ | 2,126 | | | $ | 1,397 | | | $ | 5,369 | | | $ | 3,589 | | | Rinvoq | United States | $ | 801 | | | $ | 505 | | | $ | 1,895 | | | $ | 1,228 | | | International | 309 | | | 190 | | | 819 | | | 524 | | | Total | $ | 1,110 | | | $ | 695 | | | $ | 2,714 | | | $ | 1,752 | | | Oncology | | | | | | | | | Imbruvica | United States | $ | 678 | | | $ | 849 | | | $ | 1,982 | | | $ | 2,585 | | | Collaboration revenues | 230 | | | 286 | | | 711 | | | 868 | | | Total | $ | 908 | | | $ | 1,135 | | | $ | 2,693 | | | $ | 3,453 | | | Venclexta | United States | $ | 281 | | | $ | 259 | | | $ | 811 | | | $ | 740 | | | International | 309 | | | 256 | | | 888 | | | 753 | | | Total | $ | 590 | | | $ | 515 | | | $ | 1,699 | | | $ | 1,493 | | | Epkinly | Collaboration revenues | $ | 14 | | | $ | — | | | $ | 14 | | | $ | — | | | Aesthetics | | | | | | | | | Botox Cosmetic | United States | $ | 388 | | | $ | 370 | | | $ | 1,217 | | | $ | 1,232 | | | International | 232 | | | 267 | | | 747 | | | 741 | | | Total | $ | 620 | | | $ | 637 | | | $ | 1,964 | | | $ | 1,973 | | | Juvederm Collection | United States | $ | 116 | | | $ | 125 | | | $ | 363 | | | $ | 420 | | | International | 205 | | | 227 | | | 681 | | | 686 | | | Total | $ | 321 | | | $ | 352 | | | $ | 1,044 | | | $ | 1,106 | | | Other Aesthetics | United States | $ | 255 | | | $ | 265 | | | $ | 785 | | | $ | 837 | | | International | 43 | | | 47 | | | 130 | | | 130 | | | Total | $ | 298 | | | $ | 312 | | | $ | 915 | | | $ | 967 | | | Neuroscience | | | | | | | | | Botox Therapeutic | United States | $ | 626 | | | $ | 584 | | | $ | 1,827 | | | $ | 1,641 | | | International | 122 | | | 115 | | | 388 | | | 350 | | | Total | $ | 748 | | | $ | 699 | | | $ | 2,215 | | | $ | 1,991 | | Vraylar | United States | $ | 750 | | | $ | 554 | | | $ | 1,967 | | | $ | 1,473 | | | International | 1 | | | — | | | 3 | | | — | | | Total | $ | 751 | | | $ | 554 | | | $ | 1,970 | | | $ | 1,473 | | | Duodopa | United States | $ | 25 | | | $ | 22 | | | $ | 74 | | | $ | 72 | | | International | 93 | | | 88 | | | 279 | | | 279 | | | Total | $ | 118 | | | $ | 110 | | | $ | 353 | | | $ | 351 | | | Ubrelvy | United States | $ | 230 | | | $ | 160 | | | $ | 574 | | | $ | 483 | | | International | 3 | | | — | | | 7 | | | — | | | Total | $ | 233 | | | $ | 160 | | | $ | 581 | | | $ | 483 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended September 30, | | Nine months ended September 30, | | | | (in millions) | | 2023 | | 2022 | | 2023 | | 2022 | | Qulipta | United States | $ | 131 | | | $ | 62 | | | $ | 292 | | | $ | 106 | | | International | 1 | | | — | | | 2 | | | — | | | Total | $ | 132 | | | $ | 62 | | | $ | 294 | | | $ | 106 | | | Other Neuroscience | United States | $ | 55 | | | $ | 82 | | | $ | 195 | | | $ | 400 | | | International | 6 | | | 5 | | | 15 | | | 14 | | | Total | $ | 61 | | | $ | 87 | | | $ | 210 | | | $ | 414 | | | Eye Care | | | | | | | | | Ozurdex | United States | $ | 34 | | | $ | 35 | | | $ | 107 | | | $ | 104 | | | International | 86 | | | 71 | | | 247 | | | 219 | | | Total | $ | 120 | | | $ | 106 | | | $ | 354 | | | $ | 323 | | | Lumigan/Ganfort | United States | $ | 28 | | | $ | 59 | | | $ | 142 | | | $ | 186 | | | International | 63 | | | 62 | | | 198 | | | 205 | | | Total | $ | 91 | | | $ | 121 | | | $ | 340 | | | $ | 391 | | | Alphagan/Combigan | United States | $ | 30 | | | $ | 37 | | | $ | 90 | | | $ | 161 | | | International | 40 | | | 36 | | | 116 | | | 111 | | | Total | $ | 70 | | | $ | 73 | | | $ | 206 | | | $ | 272 | | | Restasis | United States | $ | 104 | | | $ | 132 | | | $ | 265 | | | $ | 518 | | | International | 13 | | | 10 | | | 43 | | | 38 | | | Total | $ | 117 | | | $ | 142 | | | $ | 308 | | | $ | 556 | | | Other Eye Care | United States | $ | 114 | | | $ | 99 | | | $ | 334 | | | $ | 296 | | | International | 93 | | | 82 | | | 288 | | | 273 | | | Total | $ | 207 | | | $ | 181 | | | $ | 622 | | | $ | 569 | | | Other Key Products | | | | | | | | | Mavyret | United States | $ | 167 | | | $ | 190 | | | $ | 531 | | | $ | 562 | | | International | 203 | | | 193 | | | 590 | | | 599 | | | Total | $ | 370 | | | $ | 383 | | | $ | 1,121 | | | $ | 1,161 | | | Creon | United States | $ | 305 | | | $ | 336 | | | $ | 892 | | | $ | 941 | | | Linzess/Constella | United States | $ | 279 | | | $ | 262 | | | $ | 799 | | | $ | 742 | | | International | 9 | | | 9 | | | 26 | | | 24 | | | Total | $ | 288 | | | $ | 271 | | | $ | 825 | | | $ | 766 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | All other | | $ | 782 | | | $ | 925 | | | $ | 2,214 | | | $ | 3,145 | | | Total net revenues | $ | 13,927 | | | $ | 14,812 | | | $ | 40,017 | | | $ | 42,933 | |
|